Active Member
|
[China]
Address: Huafa Mansion, Binhu District, Wuxi, Jiangsu Province, China
Contact name:Soohia
Wuxi Owgels Medical Instruments Co., Ltd |
|
|
CE Antigen Fast Diagnose Test for fresh swabs COVID-19 Antigen Rapid Test Kit Clinical Fast test
PERFORMANCE CHARACTERCS
The assay demonstrated excellent clinical specificity 100% (95% CI: 98.12%-100%). Overall Agreement was 96.21% (93.34%-97.87%).
Clinical Performance of Antigen Test for fresh swabs
Using 127 fresh NP swabs which were collected freshly in Extraction Buffer in the kit to evaluate the Clinical performance of the COVID-19 Antigen Rapid Test Kit. 67 Patients who presented within 7 days of symptom onset and 60 normal persons were included in the initial primary evaluation. The Result is below:
| Sansure Covid-19 RT-PCR Assay | ||||
| Positive | Negative | Total | ||
| Kewei COVID-19 Antigen Rapid Assay | Positive | 64 | 0 | 64 |
| Negative | 3 | 60 | 63 | |
| Total | 67 | 60 | 127 | |
The assay demonstrated acceptable clinical sensitivity for fresh swab samples is 95.52% (95% CI: 87.64%-98.47%) when compared to a molecular device produced by Sansure Inc. The assay demonstrated excellent clinical specificity 100% (95% CI: 93.98%-100%). Overall Agreement was 97.64% (93.28%-99.19%). The assay demonstrated acceptable total clinical sensitivity is 91.08% (95% CI: 85.59%-94.61%) when compared to a molecular device produced by Sansure Inc. The assay demonstrated excellent clinical specificity 100% (95% CI: 98.54%-100%). Overall Agreement was 96.64% (94.44%-97.99%).
1. Overall Clinical Performance of Antigen Test Kit
A total of above 157 positive samples and 260 negative samples were detected to evaluate the clinical performance of the COVID-19 Antigen Rapid Test Kit. The Result is below:
| Sansure Covid-19 RT-PCR Assay | ||||
| Positive | Negative | Total | ||
| Kewei COVID-19 Antigen Rapid Assay | Positive | 143 | 0 | 143 |
| Negative | 14 | 260 | 274 | |
| Total | 157 | 260 | 417 | |
The assay demonstrated acceptable total clinical sensitivity is 91.08% (95% CI: 85.59%-94.61%) when compared to a molecular device produced by Sansure Inc. The assay demonstrated excellent clinical specificity 100% (95% CI: 98.54%-100%). Overall Agreement was 96.64% (94.44%-97.99%).
2. Limit of Detection(LoD)
Limit of detection (LoD) was determined by evaluating different concentrations of heat inactivated SARS-CoV-2 virus. LoD of the SARS-CoV-2 antigen rapid kit was confirmed as 38.5 TCID50/ml.
3. High-dose Hook effect
No high dose hook effect was observed when test with up to a concentration of 6.3×105 TCID50/ml of heat inactive SARS-CoV-2 virus from Academy of Military Sciences PLA China.
